查看購物車
  • English
  • Japanese
  • Korean
全基因組和EXOME定序市場—全球和區域分析：按產品類型、工作流程、應用、最終用戶和地區分類—分析和預測，2026-2036年
市場調查報告書
商品編碼
2129866

全基因組和EXOME定序市場—全球和區域分析：按產品類型、工作流程、應用、最終用戶和地區分類—分析和預測，2026-2036年

Whole Genome and Exome Sequencing Market - A Global and Regional Analysis: Focus on Product Type, Workflow, Application, End User, and Region - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 193 Pages | 商品交期: 1-5個工作天內

價格

全球全基因組和EXOME定序市場在 2025 年的初始估值為 25.3 億美元，但預計從 2026 年到 2036 年將以 14.54% 的複合年成長率顯著成長，到 2036 年達到 109.462 億美元。

關鍵市場統計數據
預測期 2026-2036
2026 年市場規模 28.154億美元
2036年的預測 109.462億美元
複合年成長率 14.54%

全球全基因組和EXOME定序市場正經歷強勁成長，這主要得益於定序技術的進步、定序成本的下降、精準醫療的日益普及以及腫瘤學、罕見疾病、生殖醫學、微生物基因組學和基因發現等領域對全面基因組分析需求的不斷成長。全基因測序(WGS) 分析幾乎整個基因組，有助於檢測編碼和非編碼變異、結構變異、拷貝數變異、粒線體變異以及特定重複序列的延伸。全外EXOME定序(WES) 專注於蛋白質轉錄區，由於其成本效益高且對疾病相關編碼變異具有很高的診斷效用，因此仍被廣泛應用。定序通量的提高、工作流程自動化、文庫樣品製備和靶向富集技術的改進、擴充性的生物資訊學、政府資助的基因組計劃以及定序在臨床和研究環境中的日益普及，都為該市場的發展提供了支持。

市場概覽

全球全基因組和EXOME定序市場涵蓋用於執行全基因組定序 (WGS) 和全外顯子定序 (WES) 工作流程的耗材、儀器和軟體。耗材包括樣品製備盒、靶向序列捕獲盒、定序試劑盒、定序池、晶片、試劑、接頭和索引產品。儀器包括桌上型定序平台，而軟體則支援鹼基辨識、品質評估、序列比對、變異識別、註釋、結果解讀和報告生成。定序即服務 (SaaS)、臨床基因檢測服務、諮詢、安裝、維護、培訓和其他專業服務不包含在本市場範圍內。

該市場已從與人類基因組計劃相關的大規模調查計畫發展成為日益標準化的臨床、製藥和人群基因組分析工作流程。次世代定序的商業化使得同時分析數百萬個DNA片段成為可能，從而大幅縮短了定序時間和降低了成本。全EXOME定序（WES）作為一種專門用於識別數千個基因編碼區變異的技術應運而生。同時，隨著定序能力和準確性的提升，全基因測序（WGS）在編碼區和非編碼區更廣泛的變異檢測方面也變得越來越實用。

全基因組定序 (WGS) 和全外顯子定序 (WES) 工作流程包括一系列步驟：DNA 品質評估、樣品製備、定序和分析。 WES 需要進一步的靶向序列捕獲以捕捉蛋白質轉錄區。定序後，一級分析包括鹼基識別和定序品質評估；二級分析包括讀段比對和突變識別；三級或臨床分析包括註釋、解讀和報告。高通量定序儀、長讀長定定序、工作流程自動化、雲端運算、人工智慧 (AI) 驅動的解讀以及基因組分析結果與電子健康記錄 (EHR)、生物樣本庫、臨床試驗系統和藥物研發平台的整合，正日益推動著這個市場的發展。

該市場中的企業專注於定序準確性、通量、週轉時間、基因組定序成本、持續使用的耗材、平台相容性、自動化樣本製備、擴充性的生物資訊學以及從樣本到報告的整合工作流程。隨著醫院、診斷實驗室、研究機構、製藥公司、生物技術公司和國家基因組計畫不斷擴大其定序業務，擁有涵蓋樣本製備、富集、定序和分析等廣泛產品系列的供應商有望獲得更強大的競爭優勢。

對產業的影響

全球全基因組和EXOME定序市場的發展動力源自於基因組學從專業研究轉向更廣泛的臨床和轉化應用的轉變。 Illumina、SOPHiA GENETICS、Thermo Fisher Scientific、QIAGEN、Agilent Technologies、Pacific Biosciences of California、Oxford Nanopore Technologies plc、F. Hoffmann-La Roche Ltd.、Danaher Corporation、New England Biolabs、MGI Tech 靶向序列捕獲 , Ltd.、Ogics Inc.等領先公司提供定序系統、持續使用的耗材、樣品製備、工作流程自動化和基因組分析功能。

全基因組定序 (WGS) 和全外顯子定序 (WES) 廣泛應用於腫瘤學、罕見疾病診斷、生殖醫學、微生物基因組學、非侵入性產前檢測、群體藥物基因體學、藥物基因組學、基因發現和藥物研發等領域。 WGS 提供廣泛的基因組覆蓋，有助於識別複雜的突變；而 WES 則提供了一種靶向性強且相對經濟高效的方法，用於檢測與疾病相關的編碼突變。這些優勢能夠提高診斷率，減少對單基因檢測的依賴，支持腫瘤表徵、生物標記發現，並為患者分層和治療研究提供資訊。

市場的影響範圍廣泛，涵蓋研究實驗室和學術機構、製藥和生物技術公司、診斷檢查室、醫院和診所等眾多領域。儘管設備利用率的提高和定序量的激增持續推動著對樣本製備和定序耗材的需求，但擴充性的軟體和基於雲端的分析技術正使檢查室能夠處理日益大規模的資料集。然而，資料儲存需求、生物資訊學的複雜性、突變解讀、保險報銷限制、隱私和網路安全問題以及基因組學專業人才的短缺等問題，仍然阻礙著這些技術的應用。

目錄

第1章：全球全基因組與EXOME定序市場：產業展望

  • 市場概覽與生態系統
  • 市場趨勢
    • 影響分析
    • 加強策略夥伴關係和合作研究，以擴大定序的可用性和應用範圍。
  • 監理情勢
    • 美國法律要求與框架
    • 歐洲的法律要求和框架
    • 日本的法律要求與框架
  • 供應鏈分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇

第2章：全球全基因組和EXOME定序市場（依產品類型分類）

  • 消耗品
    • 目標濃度試劑盒
    • 樣品製備工具包
    • 定序盒
  • 裝置
  • 軟體

第3章：全球全基因組與EXOME定序市場（依工作流程分類）

  • 全基因測序（WGS）
    • 樣品製備
    • 定序
    • 分析
  • 全EXOME定序（WES）
    • 樣品製備
    • 靶向序列捕獲
    • 定序
    • 分析

第4章：全球全基因組和EXOME定序市場（按應用領域分類）

  • 全基因測序（WGS）
    • 腫瘤學
    • 微生物
    • 非侵入性產前檢測（NIPT）
    • 其他
  • 全EXOME定序（WES）
    • 腫瘤學
    • 罕見疾病
    • 基因發現
    • 其他

第5章：全球全基因組和EXOME定序市場（依最終用戶分類）

  • 製藥和生物技術公司
  • 診斷檢測實驗室
  • 醫院和診所
  • 研究機構和學術機構
  • 其他

第6章：全球全基因組和EXOME定序市場（按地區分類）

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
  • 拉丁美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測
  • 中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 市場規模及預測

第7章：競爭標竿分析與公司概況

  • 主要發展分析（依公司分類），2023年1月至2026年7月
  • 企業市場占有率分析
  • 公司簡介
    • Illumina, Inc.
    • SOPHiA GENETICS
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies plc
    • F. Hoffmann-La Roche Ltd.
    • Danaher Corporation
    • New England Biolabs
    • MGI Tech Co., Ltd.
    • Revvity Inc.
    • Ultima Genomics, Inc.
    • Element Biosciences
    • Twist Bioscience

第8章：調查方法

Product Code: BHP1020SC

This report can be delivered within 1 working day.

Introduction to the Whole Genome and Exome Sequencing Market

The global whole genome and exome sequencing market, initially valued at $2,530.0 million in 2025, is projected to grow substantially, reaching $10,946.2 million by 2036, with a compound annual growth rate (CAGR) of 14.54% from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$2,815.4 Million
2036 Forecast$10,946.2 Million
CAGR14.54%

The global whole genome and exome sequencing market has been experiencing strong growth, driven by advances in sequencing technologies, declining sequencing costs, increasing adoption of precision medicine, and growing demand for comprehensive genomic characterization across oncology, rare diseases, reproductive health, microbial genomics, and gene discovery. Whole genome sequencing (WGS) examines nearly the entire genome and supports the detection of coding and non-coding variants, structural variants, copy-number alterations, mitochondrial variants, and selected repeat expansions. Whole exome sequencing (WES) focuses on protein-coding regions and remains widely used because of its cost-effectiveness and strong diagnostic utility for disease-associated coding variants. The market is supported by higher sequencing throughput, workflow automation, improved library preparation and target enrichment, scalable bioinformatics, government-funded genomics programs, and the increasing integration of sequencing into clinical and research environments.

Market Introduction

The global whole genome and exome sequencing market comprises the consumables, instruments, and software used to perform WGS and WES workflows. Consumables include library preparation kits, target enrichment kits, sequencing kits, flow cells, cartridges, reagents, adapters, and indexing products. Instruments include benchtop and high-throughput sequencing platforms, while software supports base calling, quality assessment, alignment, variant identification, annotation, interpretation, and reporting. Sequencing-as-a-service, clinical genetic testing services, consulting, installation, maintenance, training, and other professional services have been excluded from the market scope.

The market has evolved from the large-scale research programs associated with the Human Genome Project to increasingly standardized clinical, pharmaceutical, and population-genomics workflows. The commercialization of next-generation sequencing enabled millions of DNA fragments to be analyzed simultaneously, substantially reducing sequencing time and cost. WES emerged as a focused method for identifying coding-region variants across thousands of genes, while improvements in sequencing capacity and accuracy made WGS increasingly practical for broader variant detection across coding and non-coding regions.

WGS and WES workflows involve connected stages of DNA quality assessment, library preparation, sequencing, and analysis; WES additionally requires target enrichment to capture protein-coding regions. Following sequencing, primary analysis performs base calling and run-quality assessment, secondary analysis aligns reads and identifies variants, and tertiary or clinical analysis supports annotation, interpretation, and reporting. The market is increasingly shaped by high-throughput instruments, long-read sequencing, workflow automation, cloud computing, artificial intelligence-assisted interpretation, and the integration of genomic findings with electronic health records, biobanks, clinical-trial systems, and pharmaceutical research platforms.

Companies operating in the market are focusing on sequencing accuracy, throughput, turnaround time, cost per genome, recurring consumables, platform compatibility, automated sample preparation, scalable bioinformatics, and integrated sample-to-report workflows. As hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, biotechnology organizations, and national genomics programs expand sequencing activity, vendors with broad portfolios across preparation, enrichment, sequencing, and analysis are expected to strengthen their competitive positioning.

Industrial Impact

The global whole genome and exome sequencing market is supporting the transition of genomics from specialized research toward broader clinical and translational use. Key players such as Illumina, Inc., SOPHiA GENETICS, Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, F. Hoffmann-La Roche Ltd., Danaher Corporation, New England Biolabs, MGI Tech Co., Ltd., Revvity Inc., Ultima Genomics, Inc., Element Biosciences, and Twist Bioscience contribute sequencing systems, recurring consumables, target enrichment, library preparation, workflow automation, and genomic analysis capabilities.

WGS and WES are used across oncology, rare-disease diagnosis, reproductive health, microbial genomics, non-invasive prenatal testing, population genomics, pharmacogenomics, gene discovery, and drug development. WGS provides broad genomic coverage and supports the identification of complex variants, while WES offers a focused and comparatively cost-efficient approach for detecting disease-associated coding variants. These capabilities can improve diagnostic yield, reduce dependence on sequential single-gene testing, support tumor characterization, enable biomarker discovery, and inform patient stratification and therapeutic research.

The market's impact remains visible across research and academic institutes, pharmaceutical and biotechnology companies, diagnostic laboratories, hospitals, and clinics. Recurring demand for preparation and sequencing consumables increases with instrument utilization and sequencing volume, while scalable software and cloud-based analysis help laboratories process increasingly large datasets. However, data-storage requirements, bioinformatics complexity, variant interpretation, reimbursement limitations, privacy and cybersecurity concerns, and shortages of skilled genomics professionals continue to influence adoption.

Market Segmentation:

Segmentation 1: By Product Type

  • Consumables
  • Instruments
  • Software

Consumables Segment to Dominate the Whole Genome and Exome Sequencing Market (by Product Type)

In 2025, the consumables segment accounted for the largest share of the global whole genome and exome sequencing market. This dominance has been driven by recurring demand for library preparation kits, target enrichment kits, sequencing kits, flow cells, cartridges, and other reagents required for every sequencing run. Increasing sequencing volumes, expansion of clinical and population-scale genomic programs, and growth in the installed base of sequencing instruments are expected to sustain demand for consumables throughout the forecast period.

Segmentation 2: By Workflow

  • Whole Genome Sequencing (WGS)
    • Library Preparation
    • Sequencing
    • Analysis
  • Whole Exome Sequencing (WES)
    • Library Preparation
    • Target Enrichment
    • Sequencing
    • Analysis

Sequencing Segment to Dominate the Whole Genome and Exome Sequencing Market (by Application)

In 2025, sequencing accounted for the largest share of both the WGS and WES workflow landscapes. Within WGS, the segment growth has been supported by the extensive use of high-throughput sequencing platforms and recurring consumables required to generate genome-wide data at high coverage. Within WES, sequencing remained the highest-value workflow stage because it is central to generating high-quality exonic data for clinical diagnostics, oncology, rare-disease analysis, and translational research, despite the additional target-enrichment step.

Segmentation 3: By Application

  • Whole Genome Sequencing (WGS)
    • Oncology
    • Microbial
    • Non-Invasive Prenatal Testing (NIPT)
    • Others
  • Whole Exome Sequencing (WES)
    • Oncology
    • Rare Diseases
    • Gene Discovery
    • Others

Oncology Segment to Dominate the Whole Genome and Exome Sequencing Market (by Application)

In 2025, oncology accounted for the largest share of both the WGS and WES application landscapes. WGS supports comprehensive tumor profiling through the detection of single-nucleotide variants, structural variants, copy-number alterations, and complex genomic rearrangements. WES supports high-depth and cost-effective analysis of protein-coding regions associated with cancer development, progression, therapeutic response, and resistance. Expansion of precision oncology, cancer-genome research, biomarker discovery, and genomically informed clinical trials is expected to sustain the segment's leadership.

Segmentation 4: By End User

  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research and Academic Institutes
  • Others

Research and Academic Institutes to Dominate the Whole Genome and Exome Sequencing Market (by End User)

In 2025, research and academic institutes accounted for the largest share of the global whole genome and exome sequencing market. These organizations use WGS and WES extensively in basic and translational research, population genomics, rare-disease research, cancer-genomics projects, gene discovery, disease-mechanism studies, and genotype-phenotype analysis. Public research funding, international genomics collaborations, biobank development, large cohort studies, and declining sequencing costs are supporting the adoption of advanced sequencing platforms, consumables, and bioinformatics tools across this segment.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Singapore
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • U.A.E.
    • South Africa
    • Rest-of-Middle East and Africa

North America to Dominate the Whole Genome and Exome Sequencing Market (by Region)

In 2025, North America accounted for the largest share of the global whole genome and exome sequencing market. The region's leadership is supported by advanced genomic research and clinical infrastructure, substantial adoption of precision medicine, a strong concentration of sequencing and biotechnology companies, well-established academic and diagnostic laboratories, and extensive activity in oncology, rare diseases, reproductive health, and population genomics. The U.S. represents the largest country-level market within the region owing to its major research institutions, healthcare systems, pharmaceutical and biotechnology industry, and public and private genomic initiatives.

North America is expected to retain the largest market share through the forecast period. However, Asia-Pacific is anticipated to register the fastest growth from 2026 to 2036, with a CAGR of 15.79%, supported by expanding sequencing infrastructure, national genomics programs, rising research activity, healthcare investment, and increasing adoption across China, Japan, India, Australia, Singapore, and other regional markets.

Recent Developments in the Whole Genome and Exome Sequencing Market

  • In April 2026, Danaher Corporation's Cepheid business and Oxford Nanopore Technologies plc expanded their partnership to the next development phase, targeting a workflow for pathogen identification, antimicrobial resistance profiling, and genomic antibiotic-susceptibility-testing prediction in bloodstream infection and sepsis research.
  • In February 2026, Element Biosciences introduced VITARI, a high-throughput benchtop sequencing system priced at $689,000 and capable of delivering a high-quality whole genome at approximately $100. Pre-orders were opened, with shipments scheduled for the second half of 2026.
  • In December 2025, Oxford Nanopore Technologies plc progressed the GridION toward ISO 13485 conformity during 2025 with the intention of pursuing CE-IVD certification thereafter, while advancing ElysION as a regulated automated sample-to-answer solution.
  • In April 2025, Danaher Corporation's Cepheid business entered a partnership with Oxford Nanopore Technologies plc to use the GeneXpert system for automated sample preparation upstream of nanopore sequencing.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Growing Adoption of Precision Medicine Driving Demand for Whole Genome and Exome Sequencing: The increasing integration of precision medicine into healthcare has been a major driver of the market. WGS and WES provide comprehensive information on genetic variation associated with disease susceptibility, diagnosis, progression, and treatment response. Their use is expanding across oncology, rare diseases, cardiovascular disorders, neurological conditions, and reproductive health. The availability of genomically targeted therapies and companion diagnostics is also increasing demand for sequencing to identify patients who may benefit from specific treatments. Continued advances in next-generation sequencing, bioinformatics, artificial intelligence, reimbursement, and workflow automation are expected to support broader clinical adoption.

Market Challenges

Genomic Data Interpretation and Storage Challenges: The volume and complexity of data generated by WGS and WES remain significant challenges for market adoption. A single human genome sequenced at approximately 30X coverage generates more than 120 gigabases of data and may require approximately 50-70 GB of compressed FASTQ storage, creating substantial requirements for computing, secure storage, data transfer, and long-term archiving. Laboratories must also filter, annotate, classify, validate, and periodically reinterpret large numbers of variants before producing clinically meaningful reports. These requirements increase the total cost of genomic testing and can limit implementation among smaller hospitals and diagnostic laboratories that lack specialized bioinformatics infrastructure and trained personnel.

Market Opportunities

Expansion of Clinical Sequencing in Emerging and Underserved Markets: The limited adoption of WGS and WES across emerging economies and underserved healthcare systems represents a substantial market opportunity. Inadequate laboratory infrastructure, funding, trained personnel, bioinformatics capacity, and reimbursement continue to constrain clinical implementation, even as demand for rare-disease diagnosis, hereditary cancer testing, newborn screening, and population genomics increases. Companies offering cost-effective sequencing workflows, cloud-based data processing, artificial intelligence-enabled variant interpretation, localized genomic databases, and regional laboratory networks can reduce infrastructure barriers. Partnerships with governments, hospitals, academic institutions, and diagnostic laboratories will be important for building workforce capabilities, ethical governance, and affordable testing pathways.

How can this report add value to an organization?

Product/Innovation Strategy: The global whole genome and exome sequencing market has been divided into key segments, including product type, workflow, application, end user, and region. By understanding demand across consumables, instruments, software, library preparation, target enrichment, sequencing, and analysis, this report offers valuable insights for organizations seeking to refine their product and innovation strategies. It also identifies the requirements of WGS and WES applications in oncology, microbial genomics, NIPT, rare diseases, and gene discovery.

Growth/Marketing Strategy: Expansion of precision medicine, population genomics, rare-disease diagnosis, cancer genomics, newborn screening, reproductive health, pharmaceutical research, and clinical sequencing in emerging markets is anticipated to be central to market growth. Key developments among sequencing-platform manufacturers, consumables providers, genomic-software companies, healthcare institutions, and research organizations are shaping adoption across clinical and research environments.

Competitive Strategy: The whole genome and exome sequencing market is competitive and technology-driven, with established sequencing companies and specialized providers competing through accuracy, throughput, turnaround time, cost per genome, recurring consumables, workflow automation, platform compatibility, scalable data analysis, and clinical utility. Key market players are strengthening their positions through product launches, strategic collaborations, portfolio expansion, cloud and bioinformatics integration, and partnerships with laboratories, healthcare institutions, pharmaceutical companies, and national genomics initiatives.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts across the whole genome and exome sequencing value chain, including sequencing instrument manufacturers, reagent and consumable providers, library preparation and target enrichment companies, bioinformatics solution providers, clinical laboratories, hospitals, pharmaceutical and biotechnology companies, sequencing service providers, and academic and research institutions.
  • Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, estimates have been derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on commercially available products supporting WGS and WES workflows. The study includes consumables, instruments, and separately monetized software while excluding service-based revenues and software bundled with instruments or consumables to avoid double counting.

Primary Research

The primary sources involve industry experts from the healthcare, life sciences, and genomics sectors and stakeholders across the WGS and WES value chain. Respondents included sequencing instrument manufacturers, sequencing reagent and consumable providers, library preparation and target enrichment companies, bioinformatics and genomic data analysis solution providers, clinical laboratories, hospitals, pharmaceutical and biotechnology companies, sequencing service providers, and academic and research institutions. CEOs, vice presidents, marketing directors, product managers, bioinformatics professionals, clinical geneticists, laboratory directors, and technology and innovation directors were interviewed to obtain and verify qualitative and quantitative aspects of the research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, peer-reviewed articles, white papers, directories, and major databases, among others
  • Annual reports, regulatory filings, and investor presentations of the leading market players
  • Company websites and a detailed study of their product portfolios
  • Publications from authoritative organizations, including WHO, NIH, NHGRI, NCI, FDA, EMA, NCBI, EMBL-EBI, ClinGen, GA4GH, PubMed, and OECD
  • Paid databases, including D&B Hoovers, Bloomberg, Factiva, and Bloomberg Businessweek

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Illumina, Inc.
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies plc
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • New England Biolabs
  • MGI Tech Co., Ltd.
  • Revvity Inc.
  • Ultima Genomics, Inc.
  • Element Biosciences
  • Twist Bioscience

Table of Contents

Executive Summary

Scope and Definition

1 Global Whole Genome and Exome Sequencing Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Increasing Strategic Partnerships and Collaborations to Expand Sequencing Accessibility and Applications
  • 1.3 Regulatory Landscape
    • 1.3.1 Legal Requirements and Framework in the U.S.
    • 1.3.2 Legal Requirements and Framework in Europe
    • 1.3.3 Legal Requirements and Framework in Japan
  • 1.4 Supply Chain Analysis
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Growing Adoption of Precision Medicine Driving Demand for Whole Genome and Exome Sequencing
      • 1.5.1.2 Lower Sequencing Costs and Higher Throughput Driving Adoption of Whole Genome and Exome Sequencing
      • 1.5.1.3 Government-Funded Genomic Medicine Programs Expanding Routine Clinical Sequencing
    • 1.5.2 Market Restraints
      • 1.5.2.1 Genomic Data Interpretation and Storage Challenges
      • 1.5.2.2 Privacy, Ethical, and Cybersecurity Concerns Limiting Adoption of Whole Genome and Exome Sequencing
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Expansion of Clinical Sequencing in Emerging and Underserved Markets

2 Global Whole Genome and Exome Sequencing Market, by Product Type

  • 2.1 Consumables
    • 2.1.1 Target Enrichment Kits
    • 2.1.2 Library Preparation Kits
    • 2.1.3 Sequencing Kits
  • 2.2 Instruments
  • 2.3 Software

3 Global Whole Genome and Exome Sequencing Market, by Workflow

  • 3.1 Whole Genome Sequencing (WGS)
    • 3.1.1 Library Preparation
    • 3.1.2 Sequencing
    • 3.1.3 Analysis
  • 3.2 Whole Exome Sequencing (WES)
    • 3.2.1 Library Preparation
    • 3.2.2 Target Enrichment
    • 3.2.3 Sequencing
    • 3.2.4 Analysis

4 Global Whole Genome and Exome Sequencing Market, by Application

  • 4.1 Whole Genome Sequencing (WGS)
    • 4.1.1 Oncology
    • 4.1.2 Microbial
    • 4.1.3 Non-Invasive Prenatal Testing (NIPT)
    • 4.1.4 Others
  • 4.2 Whole Exome Sequencing (WES)
    • 4.2.1 Oncology
    • 4.2.2 Rare Diseases
    • 4.2.3 Gene Discovery
    • 4.2.4 Others

5 Global Whole Genome and Exome Sequencing Market, by End User

  • 5.1 Pharmaceutical and Biotechnology Companies
  • 5.2 Diagnostic Laboratories
  • 5.3 Hospitals and Clinics
  • 5.4 Research and Academic Institutes
  • 5.5 Others

6 Global Whole Genome and Exome Sequencing Market, by Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
      • 6.2.4.1 U.S.
        • 6.2.4.1.1 Country Overview
        • 6.2.4.1.2 Driving Factors for Market Growth
        • 6.2.4.1.3 Factors Challenging the Market
        • 6.2.4.1.4 Market Sizing and Forecast
      • 6.2.4.2 Canada
        • 6.2.4.2.1 Country Overview
        • 6.2.4.2.2 Driving Factors for Market Growth
        • 6.2.4.2.3 Factors Challenging the Market
        • 6.2.4.2.4 Market Sizing and Forecast
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
      • 6.3.4.1 U.K.
        • 6.3.4.1.1 Country Overview
        • 6.3.4.1.2 Driving Factors for Market Growth
        • 6.3.4.1.3 Factors Challenging the Market
        • 6.3.4.1.4 Market Sizing and Forecast
      • 6.3.4.2 Germany
        • 6.3.4.2.1 Country Overview
        • 6.3.4.2.2 Driving Factors for Market Growth
        • 6.3.4.2.3 Factors Challenging the Market
        • 6.3.4.2.4 Market Sizing and Forecast
      • 6.3.4.3 France
        • 6.3.4.3.1 Country Overview
        • 6.3.4.3.2 Driving Factors for Market Growth
        • 6.3.4.3.3 Factors Challenging the Market
        • 6.3.4.3.4 Market Sizing and Forecast
      • 6.3.4.4 Italy
        • 6.3.4.4.1 Country Overview
        • 6.3.4.4.2 Driving Factors for Market Growth
        • 6.3.4.4.3 Factors Challenging the Market
        • 6.3.4.4.4 Market Sizing and Forecast
      • 6.3.4.5 Spain
        • 6.3.4.5.1 Country Overview
        • 6.3.4.5.2 Driving Factors for Market Growth
        • 6.3.4.5.3 Factors Challenging the Market
        • 6.3.4.5.4 Market Sizing and Forecast
      • 6.3.4.6 Netherlands
        • 6.3.4.6.1 Country Overview
        • 6.3.4.6.2 Driving Factors for Market Growth
        • 6.3.4.6.3 Factors Challenging the Market
        • 6.3.4.6.4 Market Sizing and Forecast
      • 6.3.4.7 Rest-of-Europe
        • 6.3.4.7.1 Country Overview
        • 6.3.4.7.2 Driving Factors for Market Growth
        • 6.3.4.7.3 Factors Challenging the Market
        • 6.3.4.7.4 Market Sizing and Forecast
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
      • 6.4.4.1 China
        • 6.4.4.1.1 Country Overview
        • 6.4.4.1.2 Driving Factors for Market Growth
        • 6.4.4.1.3 Factors Challenging the Market
        • 6.4.4.1.4 Market Sizing and Forecast
      • 6.4.4.2 Japan
        • 6.4.4.2.1 Country Overview
        • 6.4.4.2.2 Driving Factors for Market Growth
        • 6.4.4.2.3 Factors Challenging the Market
        • 6.4.4.2.4 Market Sizing and Forecast
      • 6.4.4.3 India
        • 6.4.4.3.1 Country Overview
        • 6.4.4.3.2 Driving Factors for Market Growth
        • 6.4.4.3.3 Factors Challenging the Market
        • 6.4.4.3.4 Market Sizing and Forecast
      • 6.4.4.4 Australia
        • 6.4.4.4.1 Country Overview
        • 6.4.4.4.2 Driving Factors for Market Growth
        • 6.4.4.4.3 Factors Challenging the Market
        • 6.4.4.4.4 Market Sizing and Forecast
      • 6.4.4.5 Singapore
        • 6.4.4.5.1 Country Overview
        • 6.4.4.5.2 Driving Factors for Market Growth
        • 6.4.4.5.3 Factors Challenging the Market
        • 6.4.4.5.4 Market Sizing and Forecast
      • 6.4.4.6 Rest-of-Asia-Pacific
        • 6.4.4.6.1 Country Overview
        • 6.4.4.6.2 Driving Factors for Market Growth
        • 6.4.4.6.3 Factors Challenging the Market
        • 6.4.4.6.4 Market Sizing and Forecast
  • 6.5 Latin America
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Market Sizing and Forecast
      • 6.5.4.1 Brazil
        • 6.5.4.1.1 Country Overview
        • 6.5.4.1.2 Driving Factors for Market Growth
        • 6.5.4.1.3 Factors Challenging the Market
        • 6.5.4.1.4 Market Sizing and Forecast
      • 6.5.4.2 Mexico
        • 6.5.4.2.1 Country Overview
        • 6.5.4.2.2 Driving Factors for Market Growth
        • 6.5.4.2.3 Factors Challenging the Market
        • 6.5.4.2.4 Market Sizing and Forecast
      • 6.5.4.3 Rest-of-Latin America
        • 6.5.4.3.1 Country Overview
        • 6.5.4.3.2 Driving Factors for Market Growth
        • 6.5.4.3.3 Factors Challenging the Market
        • 6.5.4.3.4 Market Sizing and Forecast
  • 6.6 Middle East and Africa
    • 6.6.1 Regional Overview
    • 6.6.2 Driving Factors for Market Growth
    • 6.6.3 Factors Challenging the Market
    • 6.6.4 Market Sizing and Forecast
      • 6.6.4.1 U.A.E.
        • 6.6.4.1.1 Country Overview
        • 6.6.4.1.2 Driving Factors for Market Growth
        • 6.6.4.1.3 Factors Challenging the Market
        • 6.6.4.1.4 Market Sizing and Forecast
      • 6.6.4.2 South Africa
        • 6.6.4.2.1 Country Overview
        • 6.6.4.2.2 Driving Factors for Market Growth
        • 6.6.4.2.3 Factors Challenging the Market
        • 6.6.4.2.4 Market Sizing and Forecast
      • 6.6.4.3 Rest-of-Middle East and Africa
        • 6.6.4.3.1 Country Overview
        • 6.6.4.3.2 Driving Factors for Market Growth
        • 6.6.4.3.3 Factors Challenging the Market
        • 6.6.4.3.4 Market Sizing and Forecast

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Developments Analysis (by Company), January 2023-July 2026
  • 7.2 Company Share Analysis
  • 7.3 Company Profiles
    • 7.3.1 Illumina, Inc.
      • 7.3.1.1 Overview
      • 7.3.1.2 Top Products
      • 7.3.1.3 Top Competitors
      • 7.3.1.4 Key Personnel
      • 7.3.1.5 Analyst View
    • 7.3.2 SOPHiA GENETICS
      • 7.3.2.1 Overview
      • 7.3.2.2 Top Products
      • 7.3.2.3 Top Competitors
      • 7.3.2.4 Key Personnel
      • 7.3.2.5 Analyst View
    • 7.3.3 Thermo Fisher Scientific Inc.
      • 7.3.3.1 Overview
      • 7.3.3.2 Top Products
      • 7.3.3.3 Top Competitors
      • 7.3.3.4 Key Personnel
      • 7.3.3.5 Analyst View
    • 7.3.4 QIAGEN N.V.
      • 7.3.4.1 Overview
      • 7.3.4.2 Top Products
      • 7.3.4.3 Top Competitors
      • 7.3.4.4 Key Personnel
      • 7.3.4.5 Analyst View
    • 7.3.5 Agilent Technologies, Inc.
      • 7.3.5.1 Overview
      • 7.3.5.2 Top Products
      • 7.3.5.3 Top Competitors
      • 7.3.5.4 Key Personnel
      • 7.3.5.5 Analyst View
    • 7.3.6 Pacific Biosciences of California, Inc.
      • 7.3.6.1 Overview
      • 7.3.6.2 Top Products
      • 7.3.6.3 Top Competitors
      • 7.3.6.4 Key Personnel
      • 7.3.6.5 Analyst View
    • 7.3.7 Oxford Nanopore Technologies plc
      • 7.3.7.1 Overview
      • 7.3.7.2 Top Products
      • 7.3.7.3 Top Competitors
      • 7.3.7.4 Key Personnel
      • 7.3.7.5 Analyst View
    • 7.3.8 F. Hoffmann-La Roche Ltd.
      • 7.3.8.1 Overview
      • 7.3.8.2 Top Products
      • 7.3.8.3 Top Competitors
      • 7.3.8.4 Key Personnel
      • 7.3.8.5 Analyst View
    • 7.3.9 Danaher Corporation
      • 7.3.9.1 Overview
      • 7.3.9.2 Top Products
      • 7.3.9.3 Top Competitors
      • 7.3.9.4 Key Personnel
      • 7.3.9.5 Analyst View
    • 7.3.10 New England Biolabs
      • 7.3.10.1 Overview
      • 7.3.10.2 Top Products
      • 7.3.10.3 Top Competitors
      • 7.3.10.4 Key Personnel
      • 7.3.10.5 Analyst View
    • 7.3.11 MGI Tech Co., Ltd.
      • 7.3.11.1 Overview
      • 7.3.11.2 Top Products
      • 7.3.11.3 Top Competitors
      • 7.3.11.4 Key Personnel
      • 7.3.11.5 Analyst View
    • 7.3.12 Revvity Inc.
      • 7.3.12.1 Overview
      • 7.3.12.2 Top Products
      • 7.3.12.3 Top Competitors
      • 7.3.12.4 Key Personnel
      • 7.3.12.5 Analyst View
    • 7.3.13 Ultima Genomics, Inc.
      • 7.3.13.1 Overview
      • 7.3.13.2 Top Products
      • 7.3.13.3 Top Competitors
      • 7.3.13.4 Key Personnel
      • 7.3.13.5 Analyst View
    • 7.3.14 Element Biosciences
      • 7.3.14.1 Overview
      • 7.3.14.2 Top Products
      • 7.3.14.3 Top Competitors
      • 7.3.14.4 Key Personnel
      • 7.3.14.5 Analyst View
    • 7.3.15 Twist Bioscience
      • 7.3.15.1 Overview
      • 7.3.15.2 Top Products
      • 7.3.15.3 Top Competitors
      • 7.3.15.4 Key Personnel
      • 7.3.15.5 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Whole Genome and Exome Sequencing Market (by Scenario), $Million, 2025, 2030, and 2036
  • Figure 2: Global Whole Genome and Exome Sequencing Market (by Product Type), $Million, 2025, 2030, and 2036
  • Figure 3: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing, by Workflow), $Million, 2025, 2030, and 2036
  • Figure 4: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing, by Workflow), $Million, 2025, 2030, and 2036
  • Figure 5: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing, by Application), $Million, 2025, 2030, and 2036
  • Figure 6: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing, by Application), $Million, 2025, 2030, and 2036
  • Figure 7: Global Whole Genome and Exome Sequencing Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 8: Supply Chain Analysis, Global Whole Genome and Exome Sequencing Market
  • Figure 9: Number of Research Papers Mentioning Personalized Medicine in PubMed, 2010-2025
  • Figure 10: Decreasing Genome Sequencing Costs
  • Figure 11: Global Whole Genome and Exome Sequencing Market (by Product Type), $Million, 2025, 2030, and 2036
  • Figure 12: Global Whole Genome and Exome Sequencing Market (Consumables), $Million, 2024-2036
  • Figure 13: Global Whole Genome and Exome Sequencing Market (Target Enrichment Kits), $Million, 2024-2036
  • Figure 14: Global Whole Genome and Exome Sequencing Market (Library Preparation Kits), $Million, 2024-2036
  • Figure 15: Global Whole Genome and Exome Sequencing Market (Sequencing Kits), $Million, 2024-2036
  • Figure 16: Global Whole Genome and Exome Sequencing Market (Instruments), $Million, 2024-2036
  • Figure 17: Global Whole Genome and Exome Sequencing Market (Software), $Million, 2024-2036
  • Figure 18: Global Whole Genome and Exome Sequencing Market (by Workflow), $Million, 2025, 2030, and 2036
  • Figure 19: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS)), $Million, 2024-2036
  • Figure 20: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Library Preparation), $Million, 2024-2036
  • Figure 21: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Sequencing), $Million, 2024-2036
  • Figure 22: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Analysis), $Million, 2024-2036
  • Figure 23: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES)), $Million, 2024-2036
  • Figure 24: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Library Preparation), $Million, 2024-2036
  • Figure 25: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Target Enrichment), $Million, 2024-2036
  • Figure 26: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Sequencing), $Million, 2024-2036
  • Figure 27: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Analysis), $Million, 2024-2036
  • Figure 28: Global Whole Genome and Exome Sequencing Market (by Application), $Million, 2025, 2030, and 2036
  • Figure 29: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS)), $Million, 2024-2036
  • Figure 30: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Oncology), $Million, 2024-2036
  • Figure 31: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Microbial), $Million, 2024-2036
  • Figure 32: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Non-Invasive Prenatal Testing (NIPT)), $Million, 2024-2036
  • Figure 33: Global Whole Genome and Exome Sequencing Market (Whole Genome Sequencing (WGS), Others), $Million, 2024-2036
  • Figure 34: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES)), $Million, 2024-2036
  • Figure 35: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Oncology), $Million, 2024-2036
  • Figure 36: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Rare Diseases), $Million, 2024-2036
  • Figure 37: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Gene Discovery), $Million, 2024-2036
  • Figure 38: Global Whole Genome and Exome Sequencing Market (Whole Exome Sequencing (WES), Others), $Million, 2024-2036
  • Figure 39: Global Whole Genome and Exome Sequencing Market (by End User), $Million, 2025, 2030, and 2036
  • Figure 40: Global Whole Genome and Exome Sequencing Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2036
  • Figure 41: Global Whole Genome and Exome Sequencing Market (Diagnostic Laboratories), $Million, 2024-2036
  • Figure 42: Global Whole Genome and Exome Sequencing Market (Hospitals and Clinics), $Million, 2024-2036
  • Figure 43: Global Whole Genome and Exome Sequencing Market (Research and Academic Institutes), $Million, 2024-2036
  • Figure 44: Global Whole Genome and Exome Sequencing Market (Others), $Million, 2024-2036
  • Figure 45: North America Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 46: U.S. Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 47: Canada Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 48: Europe Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 49: U.K. Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 50: Germany Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 51: France Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 52: Italy Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 53: Spain Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 54: Netherlands Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 55: Rest-of-Europe Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 56: Asia-Pacific Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 57: China Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 58: Japan Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 59: India Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 60: Australia Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 61: Singapore Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 62: Rest-of-Asia-Pacific Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 63: Latin America Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 64: Brazil Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 65: Mexico Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 66: Rest-of-Latin America Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 67: Middle East and Africa Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 68: U.A.E. Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 69: South Africa Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 70: Rest-of-Middle East and Africa Whole Genome and Exome Sequencing Market, $Million, 2024-2036
  • Figure 71: Data Triangulation
  • Figure 72: Top-Down and Bottom-Up Approach
  • Figure 73: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Key Developments Supporting the Trend
  • Table 3: Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • Table 4: Examples of Security Breaches in Whole Genome and Exome Sequencing
  • Table 5: Global Whole Genome and Exome Sequencing Market (by Region), $Million, 2024-2036
  • Table 6: North America Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 7: U.S. Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 8: Canada Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 9: Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 10: U.K. Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 11: Germany Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 12: France Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 13: Italy Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 14: Spain Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 15: Netherlands Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 16: Rest-of-Europe Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 17: Asia-Pacific Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 18: China Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 19: Japan Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 20: India Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 21: Australia Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 22: Singapore Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 23: Rest-of-Asia-Pacific Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 24: Latin America Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 25: Brazil Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 26: Mexico Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 27: Rest-of-Latin America Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 28: Middle East and Africa Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 29: U.A.E. Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 30: South Africa Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 31: Rest-of-Middle East and Africa Whole Genome and Exome Sequencing Market (by End User), $Million, 2024-2036
  • Table 32: Global Whole Genome and Exome Sequencing Market, Key Strategies and Developments (by Company), January 2023-July 2026
  • Table 33: Global Whole Genome and Exome Sequencing Market, Company Share Analysis, 2025